Table 1
Treatment guidelines by stroke risk stratification for patients with AF.
| Low stroke risk (CHADSVASC = 0) | Moderate stroke risk (CHADSVASC = 1) | High stroke risk (CHADSVASC ≥ 2) | |
|---|---|---|---|
| AHA/ACC | No anticoagulants | OACs or aspirin (LOE IIb) | NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) are recommended over warfarin (IA) |
| ESC | No antiplatelet or anticoagulant treatment (IIIB) | OAC should be considered (IIaB) | NOAC (IA)c, VKA (IA)c,d |
| NICE | No antithrombotic therapy | Consider OAC (Warfarin or NOACs Apixaban, Dabigatran, Rivaroxaban) | Offer OAC (Warfarin or NOACs Apixaban, Dabigatran, Rivaroxaban) |
| ASIA PACIFIC | No anticoagulants | OACs | NOACs preferred to warfarin |
| CANADA | No antithrombotic therapy | OAC or Aspirin | NOACs |
| AUSTRALIA | No anticoagulants | OACs (GRADE: Strong; Evidence: Moderate). | Warfarin, NOAC (apixaban, dabigatran or rivaroxaban) (GRADE: Strong; Evidence:High.) |
| ARGENTINA | No anticoagulants | OACs or aspirin (LOE I B) | OAC (IA) with Warfarin or NOACs |
| MEXICO | Dabigatran or Warfarin (Recommended 2011) | ||
| BRAZIL | No anticoagulants | OAC (LOE IIaC) | OAC (IA) with Warfarin or NOACs |